A Study of LY3022855 In Participants With Breast or Prostate Cancer

I5F-MC-JSCB -

The main purpose of this study is to learn more about how the investigational drug, LY3022855, affects the immune system in participants with advanced breast or prostate cancer that has not responded to other treatments. Treatment may last up to 6 cycles (cycle = 6 weeks).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Breast Cancer, Prostate Cancer
What the trial is testing?
LY3022855
Could I receive a Placebo?
No
Enrollment Goal
36
Trial Dates
May 1, 2015 - Oct 4, 2017
How long will I be in the trial?
The duration of your participation depends on how well your disease responds to the study treatment.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.